Update on Business and PURE's SDC-Based Antimicrobial Food Safety Solutions
RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2022.
Summary of Results – Fiscal First Quarter Operations
- Net product sales were $467,000 and $497,000 for the fiscal first quarters ended October 31, 2022 and 2021, respectively. The decrease of $30,000 was attributable to decreased sales across our distribution and end-user network.
- Net loss for the fiscal first quarter ended October 31, 2022 was $993,000, compared to $796,000 for the fiscal first quarter ended October 31, 2021.
- Net loss, excluding share-based compensation, for the fiscal first quarter ended October 31, 2022 was $909,000, compared to $606,000 for the fiscal first quarter ended October 31, 2021.
- Net loss per share was ($0.01) for the fiscal first quarter ended October 31, 2022, compared to ($0.01) for the fiscal first quarter ended October 31, 2021.
Business Update
Corporate Accounts
PURE Hard Surface has been adopted by multiple potato processing companies, including some of the largest processors in the country. During the first quarter, multiple potato processing locations purchased and installed application equipment to remediate long-standing food safety concerns in their facilities. In addition, PURE's unique solution has been adopted in eight large snack food and bakery facilities. With multiple trials ongoing, we anticipate growth to continue in the potato, snack food and bakery industries.
Adoption in the dairy segment continues to grow, as we are now servicing several of the largest dairy processors in the country. Our combined efforts with Hydrite Chemical Co. have resulted in six additional locations using PURE Hard Surface to address various environmental concerns prevalent in the dairy industry.
Street Sales
PURE has now hired two regional managers, one located in the Midwest and the other on the West Coast. The West Coast manager is slated to start at the beginning of the calendar year and has twenty years of chemical sales experience, including sales of PURE products. The regional managers and their respective sales teams will focus on revenue generation across the janitorial, healthcare, assisted living, school, childcare, restaurant, and first responder industries.
Tom Y. Lee, Chief Executive Officer, said, "the Company experienced multiple wins this quarter with the adoption of our solution in the potato, snack food and bakery industries. Momentum into these new industries clearly shows PURE's SDC-based solutions work and provide an advantage over products currently used in the food industry," concluded Lee.
About PURE Bioscience, Inc.
PURE is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at .
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company's expectations (including with respect to Hydrite Chemical Co.), plans, business outlook, future performance, future potential revenues, expected results of the Company's marketing efforts, the execution of contracts under negotiation and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19; acceptance of the Company's current and future products and services in the marketplace, including the Company's ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company's products; the Company's ability to maintain relationships with its partners and other counterparties; the Company's ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company's ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company's SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2022 and Form 10-Q for the fiscal first quarter ended October 31, 2022. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. |
Condensed Consolidated Balance Sheets |
| | | October 31, 2022 | | | July 31, 2022 | |
| | | (Unaudited) | | | | |
Assets | | | | | | | | |
Current assets | | | | | | | | |
Cash and cash equivalents | | $ | 2,452,000 | | | $ | 3,391,000 | |
Accounts receivable | | | 252,000 | | | | 201,000 | |
Inventories, net | | | 239,000 | | | | 179,000 | |
Restricted cash | | | 75,000 | | | | 75,000 | |
Prepaid expenses | | | 54,000 | | | | 18,000 | |
Total current assets | | | 3,072,000 | | | | 3,864,000 | |
Property, plant and equipment, net | | | 627,000 | | | | 620,000 | |
Total assets | | $ | 3,699,000 | | | $ | 4,484,000 | |
Liabilities and stockholders' equity | | | | | | | | |
Current liabilities | | | | | | | | |
Accounts payable | | $ | 561,000 | | | $ | 488,000 | |
Accrued liabilities | | | 138,000 | | | | 87,000 | |
Total current liabilities | | | 699,000 | | | | 575,000 | |
Total liabilities | | | 699,000 | | | | 575,000 | |
Commitments and contingencies | | | | | | | | |
Stockholders' equity | | | | | | | | |
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | | | — | | | | — | |
Common stock, $0.01 par value: 150,000,000 shares authorized, 111,356,473 shares issued and outstanding at October 31, 2022 and at July 31, 2022 | | | 1,114,000 | | | | 1,114,000 | |
Additional paid-in capital | | | 132,163,000 | | | | 132,079,000 | |
Accumulated deficit | | | (130,277,000 | ) | | | (129,284,000 | ) |
Total stockholders' equity | | | 3,000,000 | | | | 3,909,000 | |
Total liabilities and stockholders' equity | | $ | 3,699,000 | | | $ | 4,484,000 | |
PURE Bioscience, Inc. |
Condensed Consolidated Statements of Operations |
(Unaudited) |
| | | Three months ended | |
| | | October 31, | |
| | | 2022 | | | 2021 | |
Net product sales | | $ | 467,000 | | | $ | 497,000 | |
Royalty revenue | | | 4,000 | | | | 4,000 | |
Total revenue | | | 471,000 | | | | 501,000 | |
Cost of goods sold | | | 214,000 | | | | 172,000 | |
Gross Profit | | | 257,000 | | | | 329,000 | |
Operating costs and expenses | | | | | | | | |
Selling, general and administrative | | | 1,165,000 | | | | 1,057,000 | |
Research and development | | | 78,000 | | | | 67,000 | |
Total operating costs and expenses | | | 1,243,000 | | | | 1,124,000 | |
Loss from operations | | | (986,000 | ) | | | (795,000 | ) |
Other income (expense) | | | | | | | | |
Other income (expense), net | | | (5,000 | ) | | | — | |
Interest expense, net | | | (2,000 | ) | | | (1,000 | ) |
Total other income (expense) | | | (7,000 | ) | | | (1,000 | ) |
Net loss | | $ | (993,000 | ) | | $ | (796,000 | ) |
Basic and diluted net loss per share | | $ | (0.01 | ) | | $ | (0.01 | ) |
Shares used in computing basic and diluted net loss per share | | | 111,356,473 | | | | 87,432,380 | |
PURE Bioscience, Inc. |
Condensed Consolidated Statement of Stockholders' Equity |
(Unaudited) |
| | | Common Stock | | | Additional Paid-In | | | Accumulated | | | Total Stockholders' | |
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | |
Balance July 31, 2022 | | | 111,356,473 | | | $ | 1,114,000 | | | $ | 132,079,000 | | | $ | (129,284,000 | ) | | $ | 3,909,000 | |
Share-based compensation expense - stock options | | | — | | | | — | | | | 63,000 | | | | — | | | | 63,000 | |
Share-based compensation expense - restricted stock units | | | — | | | | — | | | | 21,000 | | | | — | | | | 21,000 | |
Net loss | | | — | | | | — | | | | — | | | | (993,000 | ) | | | (993,000 | ) |
Balance October 31, 2022 (Unaudited) | | | 111,356,473 | | | $ | 1,114,000 | | | $ | 132,163,000 | | | $ | (130,277,000 | ) | | $ | 3,000,000 | |
| | | Common Stock | | | Additional Paid-In | | | Accumulated | | | Total Stockholders' | |
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity | |
Balance July 31, 2021 | | | 87,223,141 | | | $ | 873,000 | | | $ | 128,253,000 | | | $ | (125,793,000 | ) | | $ | 3,333,000 | |
Share-based compensation expense - stock options | | | — | | | | — | | | | 169,000 | | | | — | | | | 169,000 | |
Share-based compensation expense - restricted stock units | | | — | | | | — | | | | 21,000 | | | | — | | | | 21,000 | |
Issuance of common stock upon the vesting of restricted stock units | | | 650,000 | | | | 6,000 | | | | (6,000 | ) | | | — | | | | — | |
Net loss | | | — | | | | — | | | | — | | | | (796,000 | ) | | | (796,000 | ) |
Balance October 31, 2021 (Unaudited) | | | 87,873,141 | | | $ | 879,000 | | | $ | 128,437,000 | | | $ | (126,589,000 | ) | | $ | 2,727,000 | |
PURE Bioscience, Inc. |
Condensed Consolidated Statements of Cash Flows |
(Unaudited) |
| | | Three Months Ended | |
| | | October 31, | |
| | | 2022 | | | 2021 | |
Operating activities | | | | | | | | |
Net loss | | $ | (993,000 | ) | | $ | (796,000 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Share-based compensation | | | 84,000 | | | | 190,000 | |
Depreciation and amortization | | | 30,000 | | | | 58,000 | |
Changes in operating assets and liabilities: | | | | | | | | |
Accounts receivable | | | (51,000 | ) | | | 130,000 | |
Inventories | | | (60,000 | ) | | | 20,000 | |
Prepaid expenses | | | (36,000 | ) | | | (36,000 | ) |
Accounts payable and accrued liabilities | | | 124,000 | | | | (142,000 | ) |
Net cash used in operating activities | | | (902,000 | ) | | | (576,000 | ) |
Investing activities | | | | | | | | |
Purchases of property, plant and equipment | | | (37,000 | ) | | | (54,000 | ) |
Net cash used in investing activities | | | (37,000 | ) | | | (54,000 | ) |
Net decrease in cash and cash equivalents, and restricted cash | | | (939,000 | ) | | | (630,000 | ) |
Cash and cash equivalents, and restricted cash at beginning of period | | | 3,466,000 | | | | 2,465,000 | |
Cash and cash equivalents, and restricted cash at end of period | | $ | 2,527,000 | | | $ | 1,835,000 | |
Reconciliation of cash and cash equivalents, and restricted cash to the condensed consolidated balance sheets | | | | | | | | |
Cash and cash equivalents | | $ | 2,452,000 | | | $ | 1,760,000 | |
Restricted cash | | $ | 75,000 | | | $ | 75,000 | |
Total cash and cash equivalents and restricted cash | | $ | 2,527,000 | | | $ | 1,835,000 | |
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Phone: 619-596-8600 ext.: 116
BusinessとPure SDCに基づく抗菌食品安全ソリューションの最新進展
カリフォルニア州ランチョクカモンガ(米国ビジネス情報)-Pure Bioscience，Inc.(OTCQB：PURE)(“PURE”，“会社”または“WE”)，特許無毒クエン酸二水素銀(SDC)抗菌剤のメーカーは，今日，2022年10月31日までの第1四半期の財務業績を発表した
業績概要−第一財期業務
- 2022年と2021年10月31日までの第1四半期の製品純売上高はそれぞれ46.7万ドルと49.7万ドルだった。30，000ドル減少したのは，我々が取り扱うネットワークとエンドユーザネットワークの売上が低下したためである
- 2022年10月31日までの第1四半期の純損失は99.3万ドルだったが、2021年10月31日までの第1四半期の純損失は79.6万ドルだった
- 2022年10月31日現在の第1期は、株式ベースの報酬を含まない純損失は909，000ドルであるのに対し、2021年10月31日現在の第1四半期は606，000ドルである
- 2022年10月31日までの第1四半期の1株当たり純損失は0.01ドルだったが、2021年10月31日までの第1四半期の1株当たり純損失は0.01ドルだった
商業動態
企業口座
Pure Hard Surfaceはすでに多くのジャガイモ加工会社に採用されており、その中にはアメリカ最大の加工業者が含まれている。第1四半期には，複数のジャガイモ加工工場が応用設備を購入して設置し，その施設に中長期的に存在する食品安全問題を救済した。また，Pureのユニークな解決策は8つの大型レジャー食品と焙煎施設で採用されている。多くの試験の進行に伴い、私たちはジャガイモ、レジャー食品、焙煎業界が引き続き増加すると予想している
私たちは今国内最大の乳製品加工業者にサービスを提供しているので、乳製品分野の採用率は引き続き増加している。Hydrite化学社との共同努力により，乳製品業界に普遍的に存在する様々な環境問題を解決するために，純硬質表面を用いた6つの地点を追加した
街頭販売
Pureは現在2人の地域マネージャーを雇い、1人は中西部、もう1人は西海岸にいる。この西海岸マネージャーはカレンダーの年初に仕事を始める予定で、純製品の販売を含む20年間の化学品販売経験を持っている。地域マネージャーおよびそれぞれの販売チームは、門番、医療、補助生活、学校、児童保育、レストラン、救急救命士業界で収入を創出することに集中する
トム·Y·リー最高経営責任者は“当社はジャガイモ、レジャー食品、ベーカリー業界で私たちの解決策を採用し、多くの勝利を収めた。これらの新業界に進出した勢いは、Pure社がSDCに基づく解決策が功を奏し、現在食品業界に使用されている製品よりも大きな利点を提供していることをはっきりと示している”と述べた
Pure Bioscience社の概要
Pureは主に食品安全分野で我々の独自の抗菌製品の開発と商業化に集中している。病原体と衛生制御による健康と環境課題に対応するための解決策を提供する。我々の技術プラットフォームは特許に基づいた安定なイオン銀であり，我々の最初の製品はクエン酸二水素銀，すなわちよく知られているSDCを含んでいる。これは広域で無毒な抗菌剤であり，他の化合物と良好な配合である。プラットフォーム技術として、SDCは市場の現有の製品と異なり、優れた治療効果を有し、毒性を低下させ、細菌耐性を軽減するためである。Pure本部はカリフォルニア州のランチョクカモンガ(サンベナディノ大都市街地)にある。PUREに関するもっと多くの情報は、アクセスしてください
前向きに述べた本プレスリリースに含まれる歴史的事実を記述しないいかなる陳述も前向きな陳述を構成する可能性があり、この用語は1995年の“個人証券訴訟改革法”に定義されている。本プレスリリースでは、会社の予想(ハイドリット化学会社の予想を含む)、計画、業務展望、将来の業績、将来の潜在収入、会社のマーケティング作業の予想結果、交渉中の契約の実行状況に関する陳述、および将来の事件、条件、業績またはその他の事項の仮定または予想に関連する任意の他の陳述は、前向きな陳述である。展望性陳述自体にリスクと不確定要素が含まれており、これらのリスクと不確定性は私たちの実際の結果がいかなる前向き陳述と大きく異なることを招く可能性がある。これらの違いをもたらすか、または促進する可能性のある要因は、企業がその提案されたビジネス計画および計画の利点を実施または他の方法で実現できなかったこと、新冠肺炎による経済および他の中断、会社の現在および将来の製品およびサービスに対する市場の受容度を含むが、これらに限定されない, 会社がPure ControlおよびPure Hard Surfaceの成功評価およびテストを顧客注文に変換する能力と、顧客が予想通りに製品を注文し、会社の製品の使用を拡大する能力、会社がパートナーおよび他の取引相手と関係を維持する能力、会社が利益を達成するために十分な収入を生成し、運営費用を減少させる能力、会社が資金を調達して持続的な運営および業務計画の実施を支援する能力、を含む。SDCに基づく技術を生肉加工における直接食品接触加工補助剤として使用し、OLR家禽加工における使用に必要なデータおよび規制承認を拡大することを含む、有効な新製品を開発し、そのような製品を得るために必要な規制承認の能力、既存の処理化学品よりも一般的に高価な顧客のSDCベースの製品に対する顧客の受容度、製造を含む第三者への依存、およびその製品の製造を含む第三者への依存。そして、同社が米国証券取引委員会(米国証券取引委員会)に提出した定期報告書に詳細に記載されている他のリスクは、2022年7月31日までの財政年度の10-K表と、2022年10月31日までの第1四半期の10-Q表を含む。あなたはこのような前向きな陳述に過度に依存してはいけません。これらの陳述は、本プレスリリースの日の状況のみを反映しています。これらの前向きな陳述を行うことにより、会社は、本プレスリリースの日後にこれらの陳述を更新して修正または変更する義務はない。
Pure Bioscience社は |
簡明総合貸借対照表 |
| | | 2022年10月31日 | | | 2022年7月31日 | |
| | | (未監査) | | | | |
資産 | | | | | | | | |
流動資産 | | | | | | | | |
現金と現金等価物 | | $ | 2,452,000 | | | $ | 3,391,000 | |
売掛金 | | | 252,000 | | | | 201,000 | |
在庫、純額 | | | 239,000 | | | | 179,000 | |
制限現金 | | | 75,000 | | | | 75,000 | |
前払い費用 | | | 54,000 | | | | 18,000 | |
流動資産総額 | | | 3,072,000 | | | | 3,864,000 | |
財産·工場·設備·純価値 | | | 627,000 | | | | 620,000 | |
総資産 | | $ | 3,699,000 | | | $ | 4,484,000 | |
負債と株主権益 | | | | | | | | |
流動負債 | | | | | | | | |
売掛金 | | $ | 561,000 | | | $ | 488,000 | |
負債を計算すべきである | | | 138,000 | | | | 87,000 | |
流動負債総額 | | | 699,000 | | | | 575,000 | |
総負債 | | | 699,000 | | | | 575,000 | |
引受金とその他の事項 | | | | | | | | |
株主権益 | | | | | | | | |
優先株、額面0.01ドル：5，000，000株の発行許可、未発行と流通株 | | | — | | | | — | |
普通株、額面0.01ドル：150，000，000株の発行を許可し、2022年10月31日と2022年7月31日に111，356，473株を発行·発行する | | | 1,114,000 | | | | 1,114,000 | |
追加実収資本 | | | 132,163,000 | | | | 132,079,000 | |
赤字を累計する | | | (130,277,000 | ) | | | (129,284,000 | ) |
株主権益総額 | | | 3,000,000 | | | | 3,909,000 | |
総負債と株主権益 | | $ | 3,699,000 | | | $ | 4,484,000 | |
Pure Bioscience社は |
簡明総合業務報告書 |
(未監査) |
| | | 3か月まで | |
| | | 十月三十一日 | |
| | | 2022 | | | 2021 | |
製品純売上高 | | $ | 467,000 | | | $ | 497,000 | |
特許権使用料収入 | | | 4,000 | | | | 4,000 | |
総収入 | | | 471,000 | | | | 501,000 | |
販売原価 | | | 214,000 | | | | 172,000 | |
毛利 | | | 257,000 | | | | 329,000 | |
運営コストと支出 | | | | | | | | |
販売、一般、行政 | | | 1,165,000 | | | | 1,057,000 | |
研究開発 | | | 78,000 | | | | 67,000 | |
総運営コストと費用 | | | 1,243,000 | | | | 1,124,000 | |
運営損失 | | | (986,000 | ) | | | (795,000 | ) |
その他の収入(費用) | | | | | | | | |
その他の収入，純額 | | | (5,000 | ) | | | — | |
利子支出，純額 | | | (2,000 | ) | | | (1,000 | ) |
その他収入合計 | | | (7,000 | ) | | | (1,000 | ) |
純損失 | | $ | (993,000 | ) | | $ | (796,000 | ) |
1株当たりの基本と償却純損失 | | $ | (0.01 | ) | | $ | (0.01 | ) |
1株当たりの基本と純損失を計算するための株式 | | | 111,356,473 | | | | 87,432,380 | |
Pure Bioscience社は |
株主権益簡明合併報告書 |
(未監査) |
| | | 普通株 | | | その他の内容 支払い済み | | | 積算 | | | 合計する 株主の | |
| | | 株 | | | 金額 | | | 資本 | | | 赤字.赤字 | | | 権益 | |
残高2022年7月31日 | | | 111,356,473 | | | $ | 1,114,000 | | | $ | 132,079,000 | | | $ | (129,284,000 | ) | | $ | 3,909,000 | |
株に基づく報酬費用--株式オプション | | | — | | | | — | | | | 63,000 | | | | — | | | | 63,000 | |
株式ベースの報酬費用−限定株式単位 | | | — | | | | — | | | | 21,000 | | | | — | | | | 21,000 | |
純損失 | | | — | | | | — | | | | — | | | | (993,000 | ) | | | (993,000 | ) |
残高2022年10月31日(監査なし) | | | 111,356,473 | | | $ | 1,114,000 | | | $ | 132,163,000 | | | $ | (130,277,000 | ) | | $ | 3,000,000 | |
| | | 普通株 | | | その他の内容 支払い済み | | | 積算 | | | 合計する 株主の | |
| | | 株 | | | 金額 | | | 資本 | | | 赤字.赤字 | | | 権益 | |
残高2021年7月31日 | | | 87,223,141 | | | $ | 873,000 | | | $ | 128,253,000 | | | $ | (125,793,000 | ) | | $ | 3,333,000 | |
株に基づく報酬費用--株式オプション | | | — | | | | — | | | | 169,000 | | | | — | | | | 169,000 | |
株式ベースの報酬費用−限定株式単位 | | | — | | | | — | | | | 21,000 | | | | — | | | | 21,000 | |
帰属制限株式単位の場合に普通株式を発行する | | | 650,000 | | | | 6,000 | | | | (6,000 | ) | | | — | | | | — | |
純損失 | | | — | | | | — | | | | — | | | | (796,000 | ) | | | (796,000 | ) |
残高2021年10月31日(監査なし) | | | 87,873,141 | | | $ | 879,000 | | | $ | 128,437,000 | | | $ | (126,589,000 | ) | | $ | 2,727,000 | |
Pure Bioscience社は |
キャッシュフロー表簡明連結報告書 |
(未監査) |
| | | 3か月まで | |
| | | 十月三十一日 | |
| | | 2022 | | | 2021 | |
経営活動 | | | | | | | | |
純損失 | | $ | (993,000 | ) | | $ | (796,000 | ) |
純損失と経営活動で使用される現金純額の調整： | | | | | | | | |
株式ベースの報酬 | | | 84,000 | | | | 190,000 | |
減価償却および償却 | | | 30,000 | | | | 58,000 | |
経営性資産と負債変動状況： | | | | | | | | |
売掛金 | | | (51,000 | ) | | | 130,000 | |
棚卸しをする | | | (60,000 | ) | | | 20,000 | |
前払い費用 | | | (36,000 | ) | | | (36,000 | ) |
売掛金と売掛金 | | | 124,000 | | | | (142,000 | ) |
経営活動のための現金純額 | | | (902,000 | ) | | | (576,000 | ) |
投資活動 | | | | | | | | |
家屋·工場·設備を購入する | | | (37,000 | ) | | | (54,000 | ) |
投資活動のための現金純額 | | | (37,000 | ) | | | (54,000 | ) |
現金および現金等価物と制限的現金純減少 | | | (939,000 | ) | | | (630,000 | ) |
期初現金および現金等価物と制限現金 | | | 3,466,000 | | | | 2,465,000 | |
現金と現金等価物、および期末制限現金 | | $ | 2,527,000 | | | $ | 1,835,000 | |
現金と現金等価物の入金、現金を簡明な総合貸借対照表に制限する | | | | | | | | |
現金と現金等価物 | | $ | 2,452,000 | | | $ | 1,760,000 | |
制限現金 | | $ | 75,000 | | | $ | 75,000 | |
現金と現金等価物および限定的な現金総額 | | $ | 2,527,000 | | | $ | 1,835,000 | |
マーク·エリオット財務副社長
Pure Bioscience社は
電話番号：619-596-8600内線：116
